ISDA

Deposition Date 2023-03-28

Release Date 2024-02-07

Last Version Date 2024-10-23

Entry Detail

PDB ID:

8S9H

Keywords:

IMMUNE SYSTEM

Title:

Crystal structure of monkey TLR7 ectodomain with compound 14

Biological Source:

Source Organism:

Macaca mulatta (Taxon ID: 9544)

Host Organism:

Drosophila melanogaster

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.44 Å

R-Value Free:

0.26

R-Value Work:

0.24

R-Value Observed:

0.24

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Toll-like receptor 7
Chain IDs:A, B
Chain Length:817
Number of Molecules:2
Biological Source:Macaca mulatta

UniProt ID:B3Y653 Pfam ID:PF13855

Ligand Molecules

NAG

SO4

ZWV

Primary Citation

Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncology.

He, L, Zhang, M.Y, Cox, M, Zhang, Q, Donnell, A.F, Zhang, Y, Tarby, C, Gill, P, Subbaiah, M.A.M, Ramar, T, Reddy, M, Puttapaka, V, Li, Y.X, Sivaprakasam, P, Critton, D, Mulligan, D, Xie, C, Ramakrishnan, R, Nagar, J, Dudhgaonkar, S, Murtaza, A, Oderinde, M.S, Schieven, G.L, Mathur, A, Gavai, A.V, Vite, G, Gangwar, S, Poudel, Y.B.Show

Acs Med.Chem.Lett. 15 189 196 (2024)

PMID: 38352849 DOI: 10.1021/acsmedchemlett.3c00456

Abstact

Small molecule toll-like receptor (TLR) 7 agonists have gathered considerable interest as promising therapeutic agents for applications in cancer immunotherapy. Herein, we describe the development and optimization of a series of novel TLR7 agonists through systematic structure-activity relationship studies focusing on modification of the phenylpiperidine side chain. Additional refinement of ADME properties culminated in the discovery of compound 14, which displayed nanomolar reporter assay activity and favorable drug-like properties. Compound 14 demonstrated excellent in vivo pharmacokinetic/pharmacodynamic profiles and synergistic antitumor activity when administered in combination with aPD1 antibody, suggesting opportunities of employing 14 in immuno-oncology therapies with immune checkpoint blockade agents.

Legend

Protein

Chemical

Disease

Primary Citation of related structures